Company Filing History:
Years Active: 2009
Title: The Innovations of Jean-Marie Georges Contreras
Introduction
Jean-Marie Georges Contreras is a notable inventor based in Fegersheim, France. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds aimed at treating central nervous system (CNS) diseases. His work is characterized by a focus on glycinergic transmission and its implications for various neurological disorders.
Latest Patents
Contreras holds a patent for "Derivatives of glycinergic R(+)-2-amino-3-hydroxypropanoic acid." This patent describes the use of R(+)-2-amino-3-hydroxypropanoic acid derivatives, which are nitrogen substituted by various alkyl and alkenyl groups. These compounds are intended for the preparation of medicaments aimed at treating CNS diseases, particularly autism, schizophrenia, and Alzheimer's disease. His innovative approach addresses the need for effective treatments in these challenging areas of medicine.
Career Highlights
Jean-Marie Georges Contreras is associated with Prestwick Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work has led to the creation of novel therapeutic agents that hold promise for improving the quality of life for individuals affected by CNS disorders. With a patent portfolio that includes 1 patent, he has established himself as a key figure in his field.
Collaborations
Throughout his career, Contreras has collaborated with esteemed colleagues such as Kathleen E Clarence-Smith and Laurence Nathalie Deyon. These partnerships have fostered a collaborative environment that enhances the innovation process and contributes to the advancement of medical science.
Conclusion
Jean-Marie Georges Contreras exemplifies the spirit of innovation in the pharmaceutical industry. His dedication to developing new treatments for CNS diseases highlights the importance of research and collaboration in addressing complex health challenges. His contributions will undoubtedly continue to impact the field positively.